Tibes R - Search Results

1

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.

Chaudhuri L, Vincelette ND, Koh BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH, Tibes R. Chaudhuri L, et al. Among authors: tibes r. Haematologica. 2014 Apr;99(4):688-96. doi: 10.3324/haematol.2013.093187. Epub 2013 Oct 31. Haematologica. 2014. PMID: 24179152 Free PMC article.

2

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?

Tibes R, Mesa RA. Tibes R, et al. Leuk Lymphoma. 2011 Jul;52(7):1178-87. doi: 10.3109/10428194.2011.566952. Epub 2011 May 23. Leuk Lymphoma. 2011. PMID: 21599574 Review.

3

Blood consult: resistant and progressive essential thrombocythemia.

Tibes R, Mesa RA. Tibes R, et al. Blood. 2011 Jul 14;118(2):240-2. doi: 10.1182/blood-2011-01-327213. Epub 2011 May 23. Blood. 2011. PMID: 21606481 Free article. No abstract available.

4

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?

Kundranda MN, Tibes R, Mesa RA. Kundranda MN, et al. Among authors: tibes r. Curr Hematol Malig Rep. 2012 Mar;7(1):78-86. doi: 10.1007/s11899-011-0107-9. Curr Hematol Malig Rep. 2012. PMID: 22170483 Review.

5

RNAi screening of the kinome with cytarabine in leukemias.

Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME, Gonzales IM, Demuth T, Slack J, Mesa RA, Braggio E, Yin HH, Arora S, Azorsa DO. Tibes R, et al. Blood. 2012 Mar 22;119(12):2863-72. doi: 10.1182/blood-2011-07-367557. Epub 2012 Jan 20. Blood. 2012. PMID: 22267604 Free PMC article.

6

Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques.

Tibes R, Mesa RA. Tibes R, et al. Leuk Res. 2012 Jun;36(6):664-71. doi: 10.1016/j.leukres.2012.02.027. Epub 2012 Mar 28. Leuk Res. 2012. PMID: 22459332 Review.

7

JAK2 inhibitors and their impact in myeloproliferative neoplasms.

Geyer HL, Tibes R, Mesa RA. Geyer HL, et al. Among authors: tibes r. Hematology. 2012 Apr;17 Suppl 1:S129-32. doi: 10.1179/102453312X13336169156375. Hematology. 2012. PMID: 22507800

8

Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.

Cherington C, Slack JL, Leis J, Adams RH, Reeder CB, Mikhael JR, Camoriano J, Noel P, Fauble V, Betcher J, Higgins MS, Gillette-Kent G, Tremblay LD, Peterson ME, Olsen JJ, Tibes R, Mesa RA. Cherington C, et al. Among authors: tibes r. Leuk Res. 2012 Sep;36(9):1147-51. doi: 10.1016/j.leukres.2012.04.021. Epub 2012 May 11. Leuk Res. 2012. PMID: 22578777

9

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

Tibes R, Bogenberger JM, Geyer HL, Mesa RA. Tibes R, et al. Expert Opin Investig Drugs. 2012 Dec;21(12):1755-74. doi: 10.1517/13543784.2012.721352. Epub 2012 Sep 19. Expert Opin Investig Drugs. 2012. PMID: 22991927 Review.

10

MPN blast phase: clinical challenge and assessing response.

Mesa RA, Tibes R. Mesa RA, et al. Among authors: tibes r. Leuk Res. 2012 Dec;36(12):1496-7. doi: 10.1016/j.leukres.2012.08.026. Epub 2012 Sep 19. Leuk Res. 2012. PMID: 22999527 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page